Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
MorphoSys AG ADR is a biotechnology business based in the US. MorphoSys AG ADR shares (MOR) are listed on the NASDAQ and all prices are listed in US Dollars. MorphoSys AG ADR employs 648 staff and has a trailing 12-month revenue of around $195.1 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $4.46 |
|---|---|
| 52-week range | $4.07 - $12.61 |
| 50-day moving average | $5.22 |
| 200-day moving average | $6.45 |
| Wall St. target price | $13.45 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-4.61 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.46 from 2022-09-23
| 1 week (2022-09-16) | -14.56% |
|---|---|
| 1 month (2022-08-25) | -5.11% |
| 3 months (2022-06-24) | -9.90% |
| 6 months (2022-03-24) | -38.65% |
| 1 year (2021-09-24) | -63.38% |
|---|---|
| 2 years (2020-09-25) | -85.90% |
| 3 years (2019-09-25) | 27.99 |
| 5 years (2017-09-21) | N/A |
| Revenue TTM | $195.1 million |
|---|---|
| Gross profit TTM | $147.4 million |
| Return on assets TTM | -8.47% |
| Return on equity TTM | -296.68% |
| Profit margin | 0% |
| Book value | $1.04 |
| Market capitalisation | $698.3 million |
TTM: trailing 12 months
We're not expecting MorphoSys AG ADR to pay a dividend over the next 12 months.
Over the last 12 months, MorphoSys AG ADR's shares have ranged in value from as little as $4.07 up to $12.61. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MorphoSys AG ADR's is 0.975. This would suggest that MorphoSys AG ADR's shares are less volatile than average (for this exchange).
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
We’ve rounded up stats on some of the most popular wheat stocks, along with information on how these stocks compare and how to invest.